Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.55 |
| ▸ | GUSB | P08236 | 2/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222479 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL10354337 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL17526500 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL15921159 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL8431187 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL10584652 | 1.00 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL968058 | 0.98 | GNAO1 (0.52) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL8283698 | 0.91 | GNAI3 (0.43) | GNAO1GNAI3GNAI1SIGMAR1S1PR1 | |
| SCHEMBL11108890 | 0.87 | GNAI3 (0.47) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL9628389 | 0.87 | GNAI3 (0.47) | GNAO1GNAI3GNAI1GUSBEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20150111815-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | S & T GLOBAL INC (US) | 2015-04-23 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | GNAO1 1373/4885GNAI3 3092/4885GNAI1 2405/4885 |
| US-20150111815-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HAVCR2, TSLP, HLA-DRB1 | GNAO1 4563/4885GNAI3 1636/4885GNAI1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.